Novavax (NASDAQ:NVAX) Rating Increased to Hold at Wall Street Zen

Key Points

• Wall Street Zen upgraded Novavax from “Sell” to “Hold,” while the broader analyst consensus remains “Hold,” with five Buy, two Hold, and two Sell ratings and an average price target of $14.
• Novavax reported quarterly losses of $0.32 per share, beating estimates of $0.38, and revenue of $56.7 million versus expectations of $52.5 million; however, revenue fell 76.2% year over year and the company remained unprofitable.
• The stock opened at $9.42, within a 52-week range of $6.20 to $11.97. Hedge funds and other institutional investors own approximately 53.04% of Novavax shares.

Novavax (NASDAQ:NVAX - Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a note issued to investors on Saturday, Wall Street Zen reports.

Several other research firms have also commented on NVAX. Weiss Ratings reiterated a "sell (d)" rating on shares of Novavax in a research note on Tuesday, August 4th. BTIG Research restated a "buy" rating and issued a $19.00 target price on shares of Novavax in a research note on Thursday, June 11th. Finally, Zacks Research lowered Novavax from a "strong-buy" rating to a "hold" rating in a report on Thursday, August 6th. Five research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat, Novavax currently has a consensus rating of "Hold" and a consensus price target of $14.00.

Novavax Price Performance

NASDAQ NVAX opened at $9.42 on Friday. The company has a fifty day moving average price of $8.62 and a 200-day moving average price of $9.02. The firm has a market cap of $1.55 billion, a price-to-earnings ratio of -6.20 and a beta of 2.45. Novavax has a 1 year low of $6.20 and a 1 year high of $11.97.

Novavax (NASDAQ:NVAX - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, beating analysts' consensus estimates of ($0.38) by $0.06. Novavax had a negative net margin of 59.87% and a negative return on equity of 14.82%. The company had revenue of $56.70 million for the quarter, compared to analyst estimates of $52.51 million. During the same period last year, the firm earned $0.62 earnings per share. The firm's revenue was down 76.2% on a year-over-year basis. On average, research analysts anticipate that Novavax will post -0.47 EPS for the current fiscal year.

Hedge Funds Weigh In On Novavax

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Quarry LP purchased a new stake in Novavax during the third quarter worth about $33,000. Duncker Streett & Co. Inc. boosted its stake in Novavax by 917.3% in the first quarter. Duncker Streett & Co. Inc. now owns 4,242 shares of the biopharmaceutical company's stock valued at $35,000 after acquiring an additional 3,825 shares during the last quarter. KBC Group NV grew its position in shares of Novavax by 34.9% during the 1st quarter. KBC Group NV now owns 4,746 shares of the biopharmaceutical company's stock valued at $39,000 after acquiring an additional 1,229 shares during the period. Allworth Financial LP grew its position in shares of Novavax by 292.5% during the 2nd quarter. Allworth Financial LP now owns 4,353 shares of the biopharmaceutical company's stock valued at $41,000 after acquiring an additional 3,244 shares during the period. Finally, Integrated Wealth Concepts LLC purchased a new stake in shares of Novavax during the 2nd quarter worth approximately $42,000. 53.04% of the stock is owned by hedge funds and other institutional investors.

More Novavax News

Here are the key news stories impacting Novavax this week:

• Positive Sentiment: Novavax outperformed the broader market in the most recent session, according to Zacks. The article highlights the stock’s relative strength, although it does not identify a new fundamental catalyst. Novavax (NVAX) Laps the Stock Market: Here's Why
• Neutral Sentiment: Novavax presented at Citigroup’s Biopharma Back to School Summit, giving investors an opportunity to assess management’s strategy, pipeline and commercial outlook. No specific new deal, clinical update or financial guidance change was provided in the available summary. Novavax Presents at Citigroup’s Biopharma Back to School Summit 2026
• Neutral Sentiment: Reported short-interest data showed zero shares and a zero-day short-interest ratio for both periods. Because the figures appear anomalous, they do not provide a reliable indication of short-covering pressure or bearish positioning.
• Negative Sentiment: One market commentary piece included Novavax among small-cap stocks viewed skeptically, emphasizing the company’s volatility and risks associated with smaller biotechnology companies. 3 Russell 2000 Stocks We’re Skeptical Of
• Negative Sentiment: Analysts’ average rating on Novavax remains “Hold,” suggesting limited conviction that the stock will deliver substantial near-term gains. Novavax Receives Average Rating of Hold from Analysts

Novavax Company Profile

Novavax, Inc is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, that specializes in the discovery, development and commercialization of next-generation vaccines to prevent serious infectious diseases. Founded in 1987, the company has built a platform based on recombinant nanoparticle technology and its proprietary Matrix-M™ adjuvant to enhance immune responses.

The company's lead product is NVX-CoV2373, a protein-based vaccine designed to elicit a robust immune response against the SARS-CoV-2 virus.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.